Gene therapy AB-1005 was first administered to a patient with multiple system atrophy (Parkinsonian type).

Published Date: 23 Nov 2023

The study is anticipated to comprise nine MSA-parkinsonian type patients, ages 35 to 75, who will be randomized 2:1 to receive either investigational AB-1005 or sham surgery. It will be double-blind and placebo-controlled.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot